XIA-1390898
References: 1. US Food and Drug Administration. Code of Federal Regulations, Title 21, Volume 5 (21CFR349). Accessed April 17, 2020.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=349&showFR=1 2. Jones L, Downie LE, Korb D, et al.
TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15(3):575-628. 3. Xiidra [package insert]. East Hanover, NJ: Novartis
Pharmaceuticals Corp; June 2020.
SHE MAY NEED MORE THAN
ARTIFICIAL TEARS TO
DISRUPT INFLAMMATION
IN DRY EYE DISEASE
1,2
Her eyes deserve a change.
Choose twice-daily Xiidra
for lasting relief that can start
as early as 2 weeks.
3
*
†
Important Safety Information (cont)
• Inclinicaltrials,themostcommonadversereactionsreportedin5-25%ofpatientswereinstillationsite
irritation,dysgeusiaandreducedvisualacuity.Otheradversereactionsreportedin1%to5%ofthepatients
were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge,
eye discomfort, eye pruritus and sinusitis.
• To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the
single-use container to their eye or to any surface.
• Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes
following administration.
• Safetyandefficacyinpediatricpatientsbelowtheageof17yearshavenotbeenestablished.
For additional safety information about XIIDRA
®
, please refer to the brief summary of Full Prescribing
Information on adjacent page.
XIIDRA, the XIIDRA logo and ii are registered trademarks of Novartis AG.
© 2020 Novartis 6/20